10.1111/cas.14457 95 SchaverienM
GLP1, Gastric Emptying, and Protein Metabolism Glucagonlike peptide1 (GLP1) receptor agonists are incretin mimetics that decelerate gastric emptying, thereby reducing postprandial glucose excursions and appetite However, the resultant prolongation of gastric residence time influences macronutrient absorption, especially protein: 1
Another direction has been to target multiple receptors involved in stimulating insulin production
Understanding the relationship between GLP-1 medications and muscle mass is essential for patients and healthcare professionals to implement protective strategies
In addition, all patients had type 1 DM, and the neuroprotective effect of liraglutide in patients with type 2 DM was unclear
Medications with narrow therapeutic windows should be monitored Fatigue during initiation: Reduced caloric intake and metabolic adjustment during the first weeks of tirzepatide can temporarily worsen fatigue
